Insider Selling: Invivyd, Inc. (NASDAQ:IVVD) Director Sells $45,261.18 in Stock

Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire sold 83,817 shares of the firm’s stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $0.54, for a total value of $45,261.18. Following the completion of the transaction, the director now directly owns 3,340,520 shares in the company, valued at $1,803,880.80. The trade was a 2.45 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Terrance Mcguire also recently made the following trade(s):

• On Monday, December 23rd, Terrance Mcguire sold 75,776 shares of Invivyd stock. The stock was sold at an average price of $0.45, for a total transaction of $34,099.20.
• On Friday, December 20th, Terrance Mcguire sold 119,805 shares of Invivyd stock. The shares were sold at an average price of $0.42, for a total transaction of $50,318.10.
• On Wednesday, December 18th, Terrance Mcguire sold 74,764 shares of Invivyd stock. The stock was sold at an average price of $0.47, for a total transaction of $35,139.08.
• On Monday, December 16th, Terrance Mcguire sold 65,359 shares of Invivyd stock. The stock was sold at an average price of $0.47, for a total value of $30,718.73.
• On Wednesday, December 11th, Terrance Mcguire sold 160,400 shares of Invivyd stock. The shares were sold at an average price of $0.59, for a total value of $94,636.00.
• On Monday, December 9th, Terrance Mcguire sold 150,000 shares of Invivyd stock. The stock was sold at an average price of $0.61, for a total value of $91,500.00.

Invivyd Price Performance

Shares of IVVD opened at $0.51 on Friday. Invivyd, Inc. has a 1 year low of $0.40 and a 1 year high of $5.20. The company has a 50 day simple moving average of $0.73 and a two-hundred day simple moving average of $0.97. The firm has a market cap of $61.00 million, a P/E ratio of -0.26 and a beta of 0.53.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Morgan Stanley reduced their target price on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a report on Wednesday, November 20th. HC Wainwright reduced their price objective on shares of Invivyd from $15.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, November 20th. EF Hutton Acquisition Co. I upgraded shares of Invivyd to a “strong-buy” rating in a research note on Wednesday, October 30th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $9.00 target price on shares of Invivyd in a report on Thursday, November 21st. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Invivyd has an average rating of “Buy” and an average target price of $7.89.

Institutional Trading of Invivyd

A number of institutional investors and hedge funds have recently bought and sold shares of IVVD. Duquesne Family Office LLC bought a new position in shares of Invivyd during the 2nd quarter valued at about $629,000. Acadian Asset Management LLC lifted its position in shares of Invivyd by 232.0% in the second quarter. Acadian Asset Management LLC now owns 678,706 shares of the company’s stock worth $745,000 after buying an additional 474,301 shares in the last quarter. Cornercap Investment Counsel Inc. bought a new position in Invivyd during the second quarter valued at approximately $86,000. Cubist Systematic Strategies LLC grew its holdings in Invivyd by 66.1% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock valued at $148,000 after buying an additional 53,499 shares in the last quarter. Finally, SG Americas Securities LLC increased its stake in Invivyd by 198.6% in the 2nd quarter. SG Americas Securities LLC now owns 37,893 shares of the company’s stock worth $42,000 after acquiring an additional 25,201 shares during the last quarter. 70.36% of the stock is currently owned by institutional investors.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.